Literature DB >> 539577

Effects of contingent payment on compliance with a naltrexone regimen.

J Grabowski, C P O'Brien, R Greenstein, J Ternes, M Long, S Steinberg-Donato.   

Abstract

The effects of several schedules of payment on duration and patterns of compliance with a naltrexone regimen were examined. Patients were paid under contingencies based on either number of doses ingested or on a fixed time schedule. Reinforcement schedules based on number of doses ingested produced more consistent treatment-oriented behavior than a time-based schedule. Covariation between behavior and alternating contingencies (A-B-A) indicated that the schedules contributed to increased duration of treatment compared to previous noncontingent payment. The issue of using extrinsic reinforcers such as monetary payment to enhance compliance is discussed and additional procedures are suggested.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 539577     DOI: 10.3109/00952997909001724

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  10 in total

Review 1.  Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.

Authors:  Stacey C Sigmon; Adam Bisaga; Edward V Nunes; Patrick G O'Connor; Thomas Kosten; George Woody
Journal:  Am J Drug Alcohol Abuse       Date:  2012-03-12       Impact factor: 3.829

Review 2.  New methods for tobacco dependence treatment research.

Authors:  Timothy B Baker; Robin Mermelstein; Linda M Collins; Megan E Piper; Douglas E Jorenby; Stevens S Smith; Bruce A Christiansen; Tanya R Schlam; Jessica W Cook; Michael C Fiore
Journal:  Ann Behav Med       Date:  2011-04

3.  A perfect platform: combining contingency management with medications for drug abuse.

Authors:  Kathleen M Carroll; Bruce J Rounsaville
Journal:  Am J Drug Alcohol Abuse       Date:  2007       Impact factor: 3.829

4.  Long-acting injectable versus oral naltrexone maintenance therapy with psychosocial intervention for heroin dependence: a quasi-experiment.

Authors:  Adam C Brooks; Sandra D Comer; Maria A Sullivan; Adam Bisaga; Kenneth M Carpenter; Wilfrid M Raby; Elmer Yu; Charles P O'Brien; Edward V Nunes
Journal:  J Clin Psychiatry       Date:  2010-07-13       Impact factor: 4.384

5.  Financial reinforcers for improving medication adherence: findings from a meta-analysis.

Authors:  Nancy M Petry; Carla J Rash; Shannon Byrne; Shehryar Ashraf; William B White
Journal:  Am J Med       Date:  2012-07-14       Impact factor: 4.965

6.  Employment-based reinforcement of adherence to oral naltrexone in unemployed injection drug users: 12-month outcomes.

Authors:  Kelly Dunn; Anthony DeFulio; Jeffrey J Everly; Wendy D Donlin; Will M Aklin; Paul A Nuzzo; Jeannie-Marie S Leoutsakos; Annie Umbricht; Michael Fingerhood; George E Bigelow; Kenneth Silverman
Journal:  Psychol Addict Behav       Date:  2014-08-18

7.  Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trial.

Authors:  Jeffrey J Everly; Anthony DeFulio; Mikhail N Koffarnus; Jeannie-Marie S Leoutsakos; Wendy D Donlin; Will M Aklin; Annie Umbricht; Michael Fingerhood; George E Bigelow; Kenneth Silverman
Journal:  Addiction       Date:  2011-05-03       Impact factor: 6.526

8.  Employment-based reinforcement of adherence to oral naltrexone treatment in unemployed injection drug users.

Authors:  Kelly E Dunn; Anthony Defulio; Jeffrey J Everly; Wendy D Donlin; Will M Aklin; Paul A Nuzzo; Jeannie-Marie S Leoutsakos; Annie Umbricht; Michael Fingerhood; George E Bigelow; Kenneth Silverman
Journal:  Exp Clin Psychopharmacol       Date:  2012-12-03       Impact factor: 3.157

Review 9.  Lost in translation? Moving contingency management and cognitive behavioral therapy into clinical practice.

Authors:  Kathleen M Carroll
Journal:  Ann N Y Acad Sci       Date:  2014-09-09       Impact factor: 5.691

Review 10.  The use of incentives to reinforce medication adherence.

Authors:  Anthony DeFulio; Kenneth Silverman
Journal:  Prev Med       Date:  2012-05-02       Impact factor: 4.018

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.